Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation

High frequency of germline RUNX1 mutations in RUNX1 mutated AML patients

(2020) Laura Simon et al.   BLOOD

Bone Marrow Morphology Associated With Germline RUNX1 Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy

(2019) Karen M Chisholm et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1

(2019) Christopher P Mill et al.   BLOOD

Diagnostic laboratory standardization and validation of platelet transmission electron microscopy

(2018) Dong Chen et al.   PLATELETS

Finding MyoD and lessons learned along the way

(2017) Andrew B. Lassar   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders

(2016) Veronique Latger-Cannard et al.   Orphanet Journal of Rare Diseases

Transcriptional Auto-Regulation of RUNX1 P1 Promoter

(2016) Milka Martinez et al.   PLoS One

Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia

(2015) J. E. Churpek et al.   BLOOD

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

(2015) Ronan T. Swords et al.   BRITISH JOURNAL OF HAEMATOLOGY

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia

(2015) I Antony-Debré et al.   LEUKEMIA

Runx1 Transcription Factor Is Required for Myoblasts Proliferation during Muscle Regeneration

(2015) Kfir Baruch Umansky et al.   PLoS Genetics

Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects

(2014) J. P. Connelly et al.   BLOOD

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

(2014) Lenka Kubiczkova et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Posttranslational modifications of RUNX1 as potential anticancer targets

(2014) S Goyama et al.   ONCOGENE

Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors

(2014) Nicolas Duployez et al.   Expert Review of Hematology

Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations

(2014) Yao-Cheng Lin et al.   Nature Communications

RUNX family members are covalently modified and regulated by PIAS1-mediated sumoylation

(2014) J-H Kim et al.   Oncogenesis

Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression

(2012) D. Bluteau et al.   BLOOD

RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization

(2012) Larissa Lordier et al.   Nature Communications

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

(2009) C. Preudhomme et al.   BLOOD

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles

(2008) R. Flaumenhaft et al.   BLOOD

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

(2008) C. J. Owen et al.   BLOOD